NYSE American - Nasdaq Real Time Price USD

BiomX Inc. (PHGE-UN)

Compare
1.0900 -0.0100 (-0.91%)
As of October 15 at 12:38 PM EDT. Market Open.
Loading Chart for PHGE-UN
DELL
  • Previous Close 1.1000
  • Open 1.1000
  • Bid 0.8700 x 800
  • Ask 1.3200 x 800
  • Day's Range 1.0800 - 1.1000
  • 52 Week Range 0.2448 - 12.0500
  • Volume 109
  • Avg. Volume 5,166
  • Market Cap (intraday) --
  • Beta (5Y Monthly) 1.30
  • PE Ratio (TTM) --
  • EPS (TTM) -1.3110
  • Earnings Date Nov 12, 2024 - Nov 18, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 16.00

BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

www.biomx.com

58

Full Time Employees

December 31

Fiscal Year Ends

--

Sector

--

Industry

Recent News: PHGE-UN

View More

Performance Overview: PHGE-UN

Trailing total returns as of 10/16/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

PHGE-UN
0.00%
MSCI WORLD
17.59%

1-Year Return

PHGE-UN
0.00%
MSCI WORLD
0.00%

3-Year Return

PHGE-UN
98.03%
MSCI WORLD
19.85%

5-Year Return

PHGE-UN
98.99%
MSCI WORLD
66.85%

Compare To: PHGE-UN

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: PHGE-UN

View More

Valuation Measures

Annual
As of
  • Market Cap

    --

  • Enterprise Value

    --

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -32.65%

  • Return on Equity (ttm)

    -121.29%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -26.25M

  • Diluted EPS (ttm)

    -1.3110

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    31.61M

  • Total Debt/Equity (mrq)

    36.08%

  • Levered Free Cash Flow (ttm)

    -17.37M

Research Analysis: PHGE-UN

View More

Earnings Per Share

Consensus EPS
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

12.00
16.00 Average
1.0900 Current
20.00 High
 

Company Insights: PHGE-UN

People Also Watch